Clinical Trials
61 trialsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
RELIEVE
Novartis
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Pharma
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc.
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
ETNA
Vertex Pharmaceuticals Incorporated
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
THYME
Amgen
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
ziMyG
UCB Pharma
roMyG
UCB Pharma
EPIC
Janssen Research & Development, LLC
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Hadassah Medical Organization
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Shanghai Jiaolian Drug Research and Development Co., Ltd
ADAPT Jr SC
argenx
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
SYNAPSE-MG
NMD Pharma A/S
TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls
National Taipei University of Nursing and Health Sciences
OCTAGON
Alexion Pharmaceuticals, Inc.
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Cartesian Therapeutics
MG-Ex
HealthPartners Institute
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
The Affiliated Hospital of Xuzhou Medical University
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
University of Missouri-Columbia
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Arcellx, Inc.
Zilucoplan for Severe gMG Exacerbations
Ohio State University
ADAPT Jr
argenx
Synergy-MG
ImmunAbs Inc.
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
IMCOMG
Fondation Ophtalmologique Adolphe de Rothschild
Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Candid Therapeutics
OPTIMAGE
Centre Hospitalier Universitaire de Nice
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
FIT to ACT-MG
Leiden University Medical Center
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Tongji Hospital
Acti-Adult
Centre Hospitalier Universitaire de Liege
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
REFINE
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Clinique Neuro-Outaouais